PEG3350 in ACLF With Hepatic Encephalopathy

Phase 4 Unknown 60 enrolled Post Graduate Institute of Medical Education and Research, Chandigarh

RandomizedParallel-groupOpen-labelTreatment

Summary

it is a single blind randomised control study which aims to study the effect of PEG3350 in resolution of overt hepatic encephalopathy in patients of acute on chronic liver failure. this will be compared with the standard of care in the management of hepatic encephalopathy.

Timeline

Start: 2018-05-20
Primary completion: 2020-05-25
Completion: 2020-08-20

Publications

Ahmed S, Premkumar M, Dhiman RK, Kulkarni AV, Imran R, Duseja A, Kaur P, Taneja S, Singh V, Mishra S, Roy A, Mehtani R. Combined PEG3350 Plus Lactulose Results in Early Resolution of Hepatic Encephalopathy and Improved 28-Day Survival in Acute-on-Chronic Liver Failure. J Clin Gastroenterol. 2022 Jan 1;56(1):e11-e19. doi: 10.1097/MCG.0000000000001450.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	polyethylene glycol	Other / unclassified	2000 ml	Other
Background	Lactulose	Other / unclassified	30 ml	Oral

PEG3350 in ACLF With Hepatic Encephalopathy

Summary

Timeline

Publications

Drugs

Indications